A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor. Circulating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby dorosłe (od 18 lat).
- •Osoby z potwierdzonym rakiem wątroby, dróg żółciowych, trzustki, przełyku, żołądka lub jelita grubego.
- •Osoby zdrowe lub z łagodnymi problemami żołądkowo-jelitowymi (do porównania).
- •Posiadanie próbek krwi pobranych wcześniej zgodnie z zasadami.
- •Zgoda na wykorzystanie anonimowych danych medycznych i demograficznych do badań.
✗ Disqualifies
- •Posiadanie innego aktywnego nowotworu.
- •Zbyt mało lub niska jakość próbki krwi.
- •Niedawno zakończone leczenie (chemioterapia, radioterapia, operacja).
- •Stan uniemożliwiający wiarygodne uczestnictwo w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Locations (1)
City of Hope Nat Medical Ctr
Duarte, United States
Trial contact
Junyong Weng, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.